Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer Read more about Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels Read more about Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
Amgen To Present At The Jefferies Global Healthcare Conference Read more about Amgen To Present At The Jefferies Global Healthcare Conference
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions Read more about Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab Read more about Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide Read more about The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis Read more about Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab Read more about FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
Amgen To Present At The Credit Suisse Annual Healthcare Conference Read more about Amgen To Present At The Credit Suisse Annual Healthcare Conference
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 Read more about Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
